Drug Trial Radar · NCT00464438
A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis
Last checked: Nov 20, 2026Latest source record: Sep 21, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
171
Actual
Start
Jun 2007
Primary completion
Sep 2008
Study completion Sep 2008
Sponsor
- Lead sponsor
- AllerganAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Apr 23, 2007
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, up to 31 days
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 7 day study to evaluate the safety and efficacy of topical gatifloxacin ophthalmic solution for the treatment of bacterial conjunctivitis in subjects from birth to 31 days of age
Conditions
- Bacterial Conjunctivitis
Interventions
gatifloxacinDrug
Day 1-6 = 1 drop of study medication three times a day
moxifloxacin 0.5% eye dropsDrug
Day 1-6 = 1 drop of study medication three times a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Patients With Clearing (Clinical Success) of Conjunctival Erythema and Conjunctival Discharge at Day 7Time frame: Day 7
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Site not named
Sacramento, California
Site not named
Whitby, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.